Pre‐transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Communications"
DOI: 10.1002/cac2.12140
Abstract: The role of pre‐hematopoietic stem cell transplantation (HSCT) cytoreduction with either induction chemotherapy (IC) or hypomethylating agents (HMAs) in treating advanced myelodysplastic syndrome (MDS) remains debatable. We aimed to evaluate pre‐HSCT strategies by comparing the… read more here.
Keywords: advanced myelodysplastic; pre transplantation; myelodysplastic syndrome; transplantation ... See more keywords
Long-term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study.
Sign Up to like & getrecommendations! Published in 2023 at "Acta haematologica"
DOI: 10.1159/000531146
Abstract: ASPIRE, a three-part, international, phase II trial (ClinicalTrials.gov identifier: NCT01440374), investigated eltrombopag efficacy and safety in patients with advanced myelodysplastic syndrome or acute myeloid leukemia, and grade 4 thrombocytopenia ( read more here.
Keywords: long term; safety; efficacy; acute myeloid ... See more keywords